Huakang Shares Terminates RMB 1.098 Billion Acquisition; Weiguang Biological Plans RMB 1.2 Billion Private Placement to Expand Capacity; Changsha Offers Up to RMB 100 Million in Incentives to Support Biomanufacturing

Huakang Shares Terminated10.98Billion-Yuan M&A

Recently, Huakang Shares announced that the company has terminated the acquisition of Henan Yuxin Sugar Alcohol Co., Ltd. through the issuance of shares and cash payment.100%Equity interests, withdraw the application documents, and sign relevant termination agreements with the counterparty to the transaction.

As the "first xylitol stock," Huakang Shares has since2021Since its listing, the company has been committed to consolidating and expanding its competitive advantages in the field of functional sugar alcohols. The acquisition of Yuxin Sugar Alcohol represents a key strategic move in this regard. This merger and acquisition took place in2024Year10Month26Launched on [date], with a transaction price of approximately10.98hundred million yuan, upon completion of the transaction, Yuxin Sugar Alcohol will become a wholly-owned subsidiary of Huakang Shares.

Public information indicates that Yuxin Sugar Alcohols is a well-known enterprise in China’s functional sugar alcohol industry. With many years of deep engagement in the sugar alcohol sector, the company boasts advanced production processes and technical expertise. Its xylitol production capacity ranks among the top in the industry, while its subsidiary maintains a large-scale xylose production capacity, ensuring stable raw material supply, high quality standards, and strong market recognition. At the time, Huakang Pharmaceutical stated that this acquisition would help strengthen the listed company’s competitive advantages in the domestic and international xylitol markets, further advancing its position as a global leader in xylitol. Moreover, the business synergy between the two parties would further consolidate the stability of the listed company’s industrial chain from raw materials to finished products, ultimately enhancing its profitability and risk resistance.

Fuxiang Pharmaceutical's Product Receives New Food Raw Material Certification

11Month27On [date], the National Health Commission officially announced that Jiangxi Fuxiang Pharmaceutical Co., Ltd. (stock code:300497) The Fusarium venenatum protein submitted by Fuxiang Biology, a subsidiary, has officially passed the safety assessment for new food raw materials and has been approved for production and sales in China. This milestone breakthrough not only marks a key leap forward for Fuxiang Pharmaceutical in the field of synthetic biology, but also injects strong momentum into the development of China’s alternative protein industry, writing a new chapter in food technology and green development.

Fuxiang Pharmaceutical’s recently approved *Fusarium venenatum* protein (brand name “Weiran Protein”) is a filamentous fungal protein with high nutritional value and sustainability. It is reported that Weiran Protein has a high protein content and contains the essential amino acids required by the human body.18rich in amino acids, dietary fiber, and minerals such as calcium, zinc, and iron. Meanwhile, the product achieves zero antibiotics, zero pesticide residues, and zero hormones, comprehensively safeguarding consumers’ food safety and health needs. It is widely applied in scenarios including cultured meat, protein beverages, baked goods, dairy alternatives, health supplements, foods for special medical purposes (FSMP), and pet food.

Weiguang Biological Plans Private Placement12¥100 Million Capacity Expansion

Recently, Shenzhen Weiguang Biological Products Co., Ltd. disclosed its response to the Shenzhen Stock Exchange’s inquiry letter and updated its application documents for the private placement of shares. The company, which specializes in blood products, plans to raise no more than15100 million yuan (inclusive), proposed to be funded by the proceeds from the share offering12¥100 Million Investment in Weiguang Biology's Intelligent Industrial Base Project,3100 million yuan to supplement working capital.

It is reported that this fundraising and production expansion by Shenzhen Weiguang Biological Products Co., Ltd. is its2024Year-on-Year Growth in Annual Blood Product Output24.72%, but sales volume of blood products decreased year-on-year5.42%。

According to the official website, Weiguang Biological was established in1985year, the sole blood products manufacturing enterprise in Shenzhen. It is primarily engaged in the research and development, production, and sales of blood products, with a product portfolio including human albumin, intravenous immunoglobulin, and others.11variety23specifications. With an annual processing capacity of650ton plasma-derived blood product manufacturing workshop and9home plasma collection stations and3a subsidiary.

Ringpu Biology: Board of Directors Re-election

11Month28On the evening of [date], Ringpu Biology announced that the company had2025Year11Month28Held the 30th Meeting of the Fifth Board of Directors on [Date](Temporary)The meeting reviewed and approved the “Proposal on the Re-election of the Board of Directors and Nomination of Candidates for Non-Independent Directors of the Sixth Board of Directors” and the “Proposal on the Re-election of the Board of Directors and Nomination of Candidates for Independent Directors of the Sixth Board of Directors.” The Board of Directors nominated candidates for non-independent directors of the Sixth Board of Directors.5Human:Mr. Li Shoujun, Mr. Xu Lei, Ms. Liu Ailing, Mr. Zhu Xiutong, and Ms. Li Rui;Nomination of Independent Director Candidates:Mr. Dong Yichun, Mr. Wang Kai, and Ms. Li Ya.

Xinhua Medical Plans to Sell No More Than5%Shares

11Month28On the evening of , Shinva Medical (600587) announced that its wholly-owned subsidiary, Huatuo International Development Co., Ltd. (hereinafter referred to as “Huatuo International”), intends to sell no more than the shares of Huajian Medical Holdings Co., Ltd. (hereinafter referred to as “Huajian Medical”) through open market transactions.5%shares.

Shinva Medical stated that, in order to focus on the development of its core business and improve asset operation efficiency, its wholly-owned subsidiary Huatuo International plans to sell no more than5%of its shares, Huatuo International will gradually implement its share reduction plan based on a reasonable assessment of Huajian Medical’s stock price, taking into account the fluctuations in Huajian Medical’s stock price and the overall trends in the capital markets; the transaction price remains undetermined.

Freda:Company's Annual Hyaluronic Acid Production Capacity420tons, with a fully integrated production base for recombinant humanized collagen established

Freda11Month28stated on the investor interaction platform that the company's annual hyaluronic acid production capacity420tons, has established a full-industry-chain production base for recombinant humanized collagen, achieving integrated production from the research, development, and manufacturing of core raw materials to the production of finished cosmetic products.

Yunsheng Biotech WinsBRCGS AGrade Certification

Recently, Zhejiang Yunsheng Synthetic Biotechnology Co., Ltd., a subsidiary of Hisun Pharmaceutical((hereinafter referred to as “Yunsheng Synthesis”))Officially ApprovedBRCGS(BRC Global Standards)Certified and AwardedAlevel assessment, becoming one of the first enterprises in China’s synthetic biology sector to receive this authoritative certification. This significant achievement not only marks Yunsheng Synthesis’s attainment of global leadership in quality control, biosafety, and international compliance, but also sets a new benchmark for the standardization and internationalization of China’s synthetic biology industry.

Maximum Reward1CNY 100 Million: Changsha Economic and Technological Development Zone Supports the Biomanufacturing Industry

Recently, the Administrative Committee of Changsha Economic and Technological Development Zone issued the “Implementation Rules (Trial) of Several Measures of Changsha Economic and Technological Development Zone on Supporting the Development of the Biomanufacturing and Medical Device Industries.”

Emphasize the introduction and cultivation of leading enterprises and service platforms in biomanufacturing. Prioritize support for newly introduced leading companies in the field of biomanufacturing, and encourage social capital to participate in basic research in the biomanufacturing sector andGMPFor facility construction, the cumulative reward for a single enterprise shall not exceed RMB 100 million. Accelerate the introduction and cultivation of leading industry public service platforms, such as Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), Contract Development and Manufacturing Organizations (CDMOs), and Contract Sales Organizations (CSOs) in the pharmaceutical sector, based on their equipment investment amount for the current year.30%Support provided, up to a maximum of500ten thousand yuan.

Jining High-Tech Zone Hosts Exchange Meeting on Synthetic Biology Industry Development

11Month25Recently, Jining High-Tech Industrial Development Zone hosted the “Smart Synthesis, Driving the Future” Exchange Conference on the Development of the Synthetic Biology Industry. Zhang Dong, Member of the Standing Committee of the Jining Municipal Party Committee and Deputy Mayor, pointed out that Jining has established a complete synthetic biology industry chain spanning from R&D innovation to large-scale manufacturing. The city has gathered high-caliber industrial talent and innovative platforms, providing fertile ground and ample space for the deep integration and iterative upgrading of the synthetic biology industry with existing industries. The development of synthetic biology aligns closely with Jining’s industrial upgrade direction, with development needs resonating in sync. He emphasized that, through this exchange conference, Jining City will build a bridge for in-depth cooperation among government, industry, academia, research, and application, promoting precise alignment between cutting-edge technologies and industrial demands, and facilitating the localization and commercialization of more innovative achievements in Jining.